StreetInsider.com News Articles

Curasight reports tumor uptake in brain cancer trial for uTREAT drug

Mon, 12 Jan 2026 13:04:09 -0400

Curasight A/S (Frankfurt: CUS) announced preliminary data from its Phase 1 clinical trial of uTREAT, a radiopharmaceutical treatment for high-grade gliomas, according to a company press release.

The first patient in the trial showed clear uptake of uTREAT in tumor tissue through positron emission tomography imaging. The signal remained visible for at least 24 hours, indicating sustained tumor binding.

The dosimetry readout aligned with company expectations and supports continued enrollment of additional glioblastoma patients. Curasight expects top-line data in the second quarter of 2026.

"The clear tumor uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical

Curasight reports tumor uptake in brain cancer trial for uTREAT drug

Mon, 12 Jan 2026 13:04:09 -0400

Curasight A/S (Frankfurt: CUS) announced preliminary data from its Phase 1 clinical trial of uTREAT, a radiopharmaceutical treatment for high-grade gliomas, according to a company press release.

The dosimetry readout aligned with company expectations and supports continued enrollment of additional glioblastoma patients. Curasight expects top-line data in the second quarter of 2026.

"The clear tumor uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical

Curasight reports tumor uptake in brain cancer trial for uTREAT drug

Mon, 12 Jan 2026 13:04:09 -0400

Curasight A/S (Frankfurt: CUS) announced preliminary data from its Phase 1 clinical trial of uTREAT, a radiopharmaceutical treatment for high-grade gliomas, according to a company press release.

The dosimetry readout aligned with company expectations and supports continued enrollment of additional glioblastoma patients. Curasight expects top-line data in the second quarter of 2026.

"The clear tumor uptake and high retention observed in aggressive glioblastoma provide early clinical validation of our uPAR-targeted radiopharmaceutical

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0400

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors

COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0400

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0400

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0400

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0400

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

Mon, 12 Jan 2026 13:03:00 -0400

Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
COPENHAGEN, Denmark, Jan. 12, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending

Altius Provides 4th Quarter 2025 Project Generation Update

Thu, 08 Jan 2026 09:09:00 -0400

ST. JOHN’S, Newfoundland--(BUSINESS WIRE)-- Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) (“Altius”) is pleased to update its Project Generation (“PG”) business activities and its public junior equities portfolio.
The market value of equities in the portfolio at December 31, 2025 was $49.3 million, compared to $44.0 million at September 30, 2025. Net portfolio investment of approximately $1.3 million was completed during the quarter.
Altius participated in the financing of new private company Centauri Minerals, added to its position in Perseverance Metals Inc. (TSX:V:PMI) and received shares of Altitude Minerals Ltd (ASX: ATT) as consideration for the previously announced vending